Tumor News and Research

RSS

Researchers describe strategy used by Oropouche virus to replicate in human cells

The strategy used by the Oropouche virus to replicate in human cells has been described for the first time by researchers at the University of São Paulo in Brazil and international collaborators in an article published in the journal PLOS Pathogens.

31 Jul 2018

Leading-edge radiation therapy offered by Loyola Medicine to broad range of cancer patients

Loyola Medicine is among the select centers that offer a broad range of cancer patients a leading-edge form of radiation therapy that is delivered during surgery.

31 Jul 2018

FDA approves first therapy for patients with rare tumors of the adrenal gland

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy.

31 Jul 2018

Ivosidenib receives FDA approval to treat acute myeloid leukemia patients with IDH1 mutation

Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

30 Jul 2018

New improved mouse model could revolutionize bone metastasis research

Researchers at Tokyo Institute of Technology propose an improved mouse model that could revolutionize bone metastasis research. Their method, which involves injecting cancer cells via the so-called caudal artery in the mouse tail, overcomes many limitations of traditional mouse models.

30 Jul 2018

Bayshore Medical Center now offers Y-90 radioembolization to treat liver tumors without surgery

Hackensack Meridian Health Bayshore Medical Center now offers Y-90 radioembolization, an advanced and minimally invasive method to treat liver tumors without surgery.

30 Jul 2018

Researchers investigate new treatment that is effective against recurrent breast cancers

What do one in five breast cancers have in common? Large amounts of a protein called HER2 (or human epidermal growth factor receptor 2).

30 Jul 2018

BRAF inhibitors may be effective at treating rare ovarian cancer, study shows

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

30 Jul 2018

Researchers discover various mechanisms of resistance to cancer therapy

An international research team under the co-direction of the University of Bern and the Netherlands Cancer Institute has discovered various mechanisms of resistance to cancer therapy. The findings help researchers to understand the self-repair of cancer cells after a therapy and thus help to fight resistant tumours more efficiently.

30 Jul 2018

Tübingen University Hospital introduces its new Elekta Unity cancer treatment system

On July 25, the radiation oncology department at Tübingen University Hospital introduced its new Elekta Unity MR-linac, a groundbreaking cancer treatment system that integrates two critical but distinct technologies in a single platform: a state-of-the-art, high field wide bore 1.5 Tesla MR imaging system and a next-generation linear accelerator.

27 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

CellMax Life receives six U.S. patents for early cancer detection blood test

CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tumor cells.

26 Jul 2018

Scientists uncover new strategy to kill tumors without harming healthy cells

Scientists at Scripps Research have uncovered a new strategy to kill tumors, including some triple-negative breast cancers, without harming healthy cells, a discovery that could lead to more ways to treat tumors while reducing side effects.

26 Jul 2018

Anti-cancer gene may switch side and promote cancer growth, shows study

It doesn't often happen that army generals switch sides in the middle of a war, but when cancer's attack is underway, it may even cause a gene that acts as the body's master defender to change allegiance.

26 Jul 2018

Study observes how nanoplastics cause damage to DNA and cell membranes in mussels

Plastic pollution is a worldwide environmental problem which worsens when this material degrades into smaller-sized particles such as microplastics and nanoplastics, the latter capable of penetrating into an organism's cells.

26 Jul 2018

New combination approach may help crush resistance to treatment in lung cancer patients

New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Study: Blood test can predict response of advanced prostate cancer patients to treatments

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

25 Jul 2018

New protein complex may explain why patients develop resistance to novel anti-cancer drugs

A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.

25 Jul 2018

Tumor News and Research

Researchers describe strategy used by Oropouche virus to replicate in human cells

Leading-edge radiation therapy offered by Loyola Medicine to broad range of cancer patients

FDA approves first therapy for patients with rare tumors of the adrenal gland

Ivosidenib receives FDA approval to treat acute myeloid leukemia patients with IDH1 mutation

New improved mouse model could revolutionize bone metastasis research

Bayshore Medical Center now offers Y-90 radioembolization to treat liver tumors without surgery

Researchers investigate new treatment that is effective against recurrent breast cancers

BRAF inhibitors may be effective at treating rare ovarian cancer, study shows

Researchers discover various mechanisms of resistance to cancer therapy

Tübingen University Hospital introduces its new Elekta Unity cancer treatment system

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

CellMax Life receives six U.S. patents for early cancer detection blood test

Scientists uncover new strategy to kill tumors without harming healthy cells

Anti-cancer gene may switch side and promote cancer growth, shows study

Study observes how nanoplastics cause damage to DNA and cell membranes in mussels

New combination approach may help crush resistance to treatment in lung cancer patients

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Study: Blood test can predict response of advanced prostate cancer patients to treatments

New protein complex may explain why patients develop resistance to novel anti-cancer drugs

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News